These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 20473066

  • 1. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.
    Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ.
    J Clin Psychopharmacol; 2010 Jun; 30(3):294-9. PubMed ID: 20473066
    [Abstract] [Full Text] [Related]

  • 2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 3. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 5. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ.
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [Abstract] [Full Text] [Related]

  • 6. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG, Fava M, Jiang Q, Tourian KA.
    Psychopharmacol Bull; 2009 Oct; 42(3):21-35. PubMed ID: 19752839
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N, Tourian KA, Hwang E, Mele L, Vialet C.
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 10. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan 03; 48():86-91. PubMed ID: 24096053
    [Abstract] [Full Text] [Related]

  • 11. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ.
    J Clin Psychopharmacol; 2011 Oct 03; 31(5):569-76. PubMed ID: 21869698
    [Abstract] [Full Text] [Related]

  • 12. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Clayton A, Bao W, Guico-Pabia CJ.
    Menopause; 2014 Aug 03; 21(8):799-806. PubMed ID: 24448103
    [Abstract] [Full Text] [Related]

  • 13. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.
    J Womens Health (Larchmt); 2015 Apr 03; 24(4):281-90. PubMed ID: 25860107
    [Abstract] [Full Text] [Related]

  • 14. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
    Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C.
    J Clin Psychopharmacol; 2010 Feb 03; 30(1):18-24. PubMed ID: 20075643
    [Abstract] [Full Text] [Related]

  • 15. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
    Kornstein SG, Guico-Pabia CJ, Fayyad RS.
    Hum Psychopharmacol; 2014 Sep 03; 29(5):492-501. PubMed ID: 25196042
    [Abstract] [Full Text] [Related]

  • 16. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.
    Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA.
    Pharmacopsychiatry; 2010 Nov 03; 43(7):271-6. PubMed ID: 20830664
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan 03; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
    Tourian KA, Padmanabhan K, Groark J, Ninan PT.
    J Clin Psychopharmacol; 2010 Aug 04; 30(4):411-6. PubMed ID: 20631558
    [Abstract] [Full Text] [Related]

  • 20. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
    Soares CN, Endicott J, Boucher M, Fayyad RS, Guico-Pabia CJ.
    CNS Spectr; 2014 Dec 04; 19(6):519-27. PubMed ID: 24571916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.